20.06

2.72% -0.56

Pre-market: 20.26 0.20 +1.00%

Novocure Ltd (NVCR)

Overview News Price History Option Chain Financials Why NVCR Down? Discussions Forecast

Novocure Ltd stock is traded at $20.06, with a volume of 616.59K. It is down -2.72% in the last 24 hours and down -7.60% over the past month. NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Previous Close:

$20.62

Open:

$20.6

24h Volume:

616.59K

Relative Volume:

0.63

Market Cap:

$2.17B

Revenue:

$577.74M

Net Income/Loss:

$-149.78M

P/E Ratio:

-14.33

EPS:

-1.4

Net Cash Flow:

$-78.21M

1W Performance:

+4.15%

1M Performance:

-7.60%

6M Performance:

+8.02%

1Y Performance:

+35.36%

1-Day Range:

$20.00

$20.87

1-Week Range:

$19.25

$21.55

52-Week Range:

$11.70

$34.13

Novocure Ltd Stock (NVCR) Company Profile

Name

Novocure Ltd

Sector

Healthcare (1169)

Industry

Medical Devices (159)

Phone

44 (0)15 3475 6700

Address

NO. 4 THE FORUM, ST. HELIER

Employee

1,453

Twitter

@novocure

Next Earnings Date

2024-10-30

Latest SEC Filings

NVCR's Discussions on Twitter

Compare NVCR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NVCR Novocure Ltd	20.06	2.17B	577.74M	-149.78M	-78.21M	-1.40
ABT Abbott Laboratories	129.89	225.27B	41.95B	13.40B	6.35B	7.65
BSX Boston Scientific Corp	95.37	140.74B	16.75B	1.85B	2.37B	1.25
SYK Stryker Corp	363.66	138.77B	22.60B	2.99B	3.49B	7.76
MDT Medtronic Plc	92.33	118.39B	33.20B	4.26B	5.47B	3.29
EW Edwards Lifesciences Corp	67.95	39.95B	5.72B	4.17B	259.90M	6.97

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-24	Upgrade	Evercore ISI	In-line → Outperform
Oct-16-24	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-20-23	Resumed	JP Morgan	Neutral
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight
Aug-04-23	Initiated	SVB Securities	Outperform
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-05-23	Reiterated	H.C. Wainwright	Buy
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy
Feb-08-22	Initiated	Loop Capital	Buy
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-20-22	Upgrade	Truist	Hold → Buy
Jan-03-22	Upgrade	Evercore ISI	Underperform → In-line
Jul-01-21	Downgrade	Mizuho	Buy → Neutral
Apr-14-21	Downgrade	Wedbush	Neutral → Underperform
Jan-25-21	Reiterated	Piper Sandler	Overweight
Sep-23-20	Initiated	Northland Capital	Outperform
Sep-18-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-17-20	Downgrade	Truist	Buy → Hold
Jun-01-20	Resumed	Oppenheimer	Perform
May-01-20	Downgrade	Oppenheimer	Outperform → Perform
Apr-09-20	Downgrade	Evercore ISI	In-line → Underperform
Mar-05-20	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-02-20	Downgrade	Evercore ISI	Outperform → In-line
Jul-29-19	Upgrade	SunTrust	Hold → Buy
Jul-26-19	Downgrade	JP Morgan	Overweight → Neutral
Jul-26-19	Downgrade	Wedbush	Outperform → Neutral
Mar-20-19	Initiated	SunTrust	Hold
Nov-02-18	Downgrade	Wells Fargo	Outperform → Market Perform
Jul-16-18	Initiated	Evercore ISI	Outperform
Apr-18-18	Reiterated	Mizuho	Buy
Feb-23-18	Reiterated	Mizuho	Buy
May-24-17	Upgrade	Wells Fargo	Market Perform → Outperform
Jul-29-16	Reiterated	Wedbush	Outperform
Jan-19-16	Initiated	Barclays	Underweight
Dec-02-15	Initiated	Deutsche Bank	Hold

View All

Novocure Ltd Stock (NVCR) Latest News

Mar 12, 2025

An Analysis of NovoCure Ltd (NVCR)’s Potential Price Growth - Knox Daily

Mar 12, 2025

Mar 11, 2025

Novocure at Leerink’s Global Healthcare Conference: Expanding TTFields - Investing.com India

Mar 11, 2025

Novocure at Leerink’s Global Healthcare Conference: Expanding TTFields By Investing.com - Investing.com UK

Mar 11, 2025

Mar 08, 2025

Principal Financial Group Inc. Invests $272,000 in NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 08, 2025

Mar 07, 2025

Novocure Ltd. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Mar 06, 2025

Truist Financial Corp Invests $340,000 in NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 06, 2025

Don't Ignore The Insider Selling In NovoCure - Simply Wall St

Mar 06, 2025

Mar 05, 2025

Novocure’s EVP sells shares worth $46,841 By Investing.com - Investing.com Australia

Mar 05, 2025

Insider Sell Alert: Frank Leonard Sells 15,036 Shares of NovoCure Ltd (NVCR) - GuruFocus.com

Mar 05, 2025

Novocure COO sells shares worth $4,634 - Investing.com India

Mar 05, 2025

Mar 04, 2025

Prediction: Novocure (NVCR) Will Beat the Market. Here's Why - MSN

Mar 04, 2025

Novocure’s chief innovation officer sells shares worth $5,071 - Investing.com India

Mar 04, 2025

Novocure’s EVP sells shares worth $46,841 - Investing.com India

Mar 04, 2025

Novocure CEO Ashley Cordova sells shares valued at $38,055 By Investing.com - Investing.com South Africa

Mar 04, 2025

Novocure CEO Ashley Cordova sells shares valued at $38,055 - Investing.com

Mar 04, 2025

Novocure COO sells shares worth $4,634 By Investing.com - Investing.com Australia

Mar 04, 2025

Novocure’s COO Paravasthu Mukund sells shares worth $39,687 By Investing.com - Investing.com Australia

Mar 04, 2025

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference - Yahoo Finance

Mar 04, 2025

NovoCure (NASDAQ:NVCR) Lowered to “Sell” Rating by StockNews.com - Defense World

Mar 04, 2025

Mar 03, 2025

Novocure executive sells shares for $296,256 By Investing.com - Investing.com South Africa

Mar 03, 2025

Novocure’s COO Paravasthu Mukund sells shares worth $39,687 - Investing.com India

Mar 03, 2025

Novocure CEO Ashley Cordova disposes shares worth $266,126 - Investing.com India

Mar 03, 2025

Novocure CEO Ashley Cordova disposes shares worth $266,126 By Investing.com - Investing.com Canada

Mar 03, 2025

Q1 Earnings Estimate for NovoCure Issued By Leerink Partnrs - Defense World

Mar 03, 2025

Mar 02, 2025

New York State Common Retirement Fund Increases Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 02, 2025

Mar 01, 2025

Some Confidence Is Lacking In NovoCure Limited (NASDAQ:NVCR) As Shares Slide 25% - Simply Wall St

Mar 01, 2025

Los Angeles Capital Management LLC Acquires 55,334 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat

Mar 01, 2025

Rhumbline Advisers Buys 3,115 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 01, 2025

Feb 28, 2025

NovoCure (NASDAQ:NVCR) Posts Earnings Results, Misses Expectations By $0.27 EPS - MarketBeat

Feb 28, 2025

Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus.com

Feb 28, 2025

Commit To Buy NovoCure At $13, Earn 22.3% Using Options - Nasdaq

Feb 28, 2025

NovoCure (NASDAQ:NVCR) Shares Gap Down After Earnings Miss - MarketBeat

Feb 28, 2025

NovoCure Full Year 2024 Earnings: EPS Misses Expectations - Simply Wall St

Feb 28, 2025